The Management Board of Celon Pharma S.A. (\u201cthe Company\u201d), acting pursuant to Article 395 \u00a7 1, Article 399 \u00a7 1, Article 402 (1) and Article 402 (2) of the Commercial Companies Code, hereby convenes the Ordinary General Meeting (\u201cOrdinary General Meeting\u201d) on June 21, 2024 to be held at 09:30 AM at the Company’s Research and Development Center in Kazu\u0144 Nowy at ul. Marymoncka 15.<\/p>\n\n\n\n
The suggested agenda is as follows:<\/p>\n\n\n\n
1. Opening of the Ordinary General Meeting.<\/p>\n\n\n\n
2. Election of the Chairperson of the Ordinary General Meeting.<\/p>\n\n\n\n
3. Confirmation that the Ordinary General Meeting has been convened correctly and has the capacity to adopt binding resolutions.<\/p>\n\n\n\n
4. Election of the Returning Committee of the Ordinary General Meeting.<\/p>\n\n\n\n
5. Adoption of the agenda of the Ordinary General Meeting.<\/p>\n\n\n\n
6. Examination of the Management Board\u2019s Report on the Company\u2019s business activities for the year 2023, the Company\u2019s Financial Statements for the financial year 2023, the Management Board\u2019s recommendation on the coverage of loss and payment of the dividend for the financial year 2023.<\/p>\n\n\n\n
7. Examination of the Supervisory Board\u2019s Report for the financial year 2023 prepared pursuant to the requirement of Article 382(3)(3) of the Commercial Companies Code and taking into account requirements specified in the Best Practice for GPW-Listed Companies 2021.<\/p>\n\n\n\n
8. Adoption of a resolution on approving the Management Board\u2019s Report on the Company\u2019s business activities for the year 2023.<\/p>\n\n\n\n
9. Adoption of a resolution on approving the Company\u2019s Financial Statements for the financial year 2023;<\/p>\n\n\n\n
10. Adoption of a resolution on the coverage of loss and payment of the dividend for the financial year 2023.<\/p>\n\n\n\n
11. Adoption of a resolution on approving the Supervisory Board\u2019s Report for the financial year 2023 prepared pursuant to the requirement of Article 382(3)(3) of the Commercial Companies Code taking into account requirements specified in the Best Practice for GPW-Listed Companies 2021.<\/p>\n\n\n\n
12. Adoption of resolutions on acknowledging the fulfilment of duties by Members of the Management Board in 2023.<\/p>\n\n\n\n
13. Adoption of resolutions on acknowledging the fulfilment of duties by Members of the Supervisory Board in 2023.<\/p>\n\n\n\n
14. Adoption of a resolution on issuing an opinion on the “Report on remuneration of Members of the Management Board and the Supervisory Board of Celon Pharma S.A. for the period 01.01.2023-31.12.2023\u201d.<\/p>\n\n\n\n
15. Adoption of a resolution on increasing the Company\u2019s share capital by way of issue of E-series ordinary bearer shares with exclusion of E-series share subscription rights of existing shareholders in full.<\/p>\n\n\n\n
16. Adoption of a resolution on the amendment of the Company\u2019s articles of association.<\/p>\n\n\n\n
17. Any other business.<\/p>\n\n\n\n
18. Closing of the General Meeting.<\/p>\n\n\n\n
In this current report, the Company is attaching the full notice on convening the Ordinary General Meeting and the content of resolution drafts. The remaining documents, i.e. The Report of the Supervisory Board of Celon Pharma S.A. for the financial year 2023, the Report on remuneration of Members of the Management Board and the Supervisory Board of Celon Pharma S.A. for the period 01.01.2022 – 31.12.2022 and the report of the independent statutory auditor of the attestation services covering evaluation of this report will be provided immediately after having been adopted by the Supervisory Board and after the Company has received the statutory auditor’s report.<\/p>\n","protected":false},"excerpt":{"rendered":"